Mosquirix (RTS,S)

A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria

Kyle J Wilby BSP ACPR, PharmD; Tim TY Lau PharmD ACPR FCSHP; Samuel E Gilchrist MSc (Pharm), PhD; Mary HH Ensom PharmD FASHP FCCP FCSHP FCAHS


The Annals of Pharmacotherapy. 2012;46(3):384-393. 

In This Article


Development of a vaccine for malaria is a medical breakthrough that has potential to prevent significant disease worldwide. Mosquirix (RTS,S) has demonstrated efficacy and safety in Phase 1 and 2 trials and recent Phase 3 trials. The major challenges that need to be addressed include determination of duration of immunity, assessment of vaccine cost-effectiveness, its use in special populations, and its dissemination in endemic regions. Pending further results from Phase 3 trials, Mosquirix has the potential to become the benchmark as the first vaccine against malaria that is highly effective and safe.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.